Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
Yan Zhao(Peking University), Jianzhong Zhang(Chinese Academy of Sciences), Yangfeng Ding(Shanghai Stomatological Hospital), Xiuqin Dong(Guangdong Academy of Medical Sciences), Rongjun Liu(Sichuan University), Aik Han Goh, Rupeng Wang(Army Medical University), Xiaohua Tao(Zhejiang Provincial People's Hospital), Qianjin Lu(Central South University), Liming Wu(Hangzhou First People's Hospital), Litao Zhang(Tianjin University of Traditional Chinese Medicine), Zhiguo Zhang(Wuhan General Hospital of Guangzhou), Jianyun Lu(Central South University), Chao Ji(Zhongshan Hospital of Xiamen University)
Cited by 59
Related Papers
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus
|Nature Genetics|2009|951
Demethylation of <i>CD40LG</i> on the Inactive X in T Cells from Women with Lupus
|The Journal of Immunology|2007|466
Induced Regulatory T Cells: Their Development, Stability, and Applications
|Trends in Immunology|2016|451
TLR2 and TLR4 in Autoimmune Diseases: a Comprehensive Review
|Clinical Reviews in Allergy & Immunology|2013|372